Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Oct 12, 2021 (5 years ago)

AllerClear D-24 hr (Loratadine and Pseudoephedrine Sulfate)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Moisture Limits

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

AllerClear D-24 hr, (Loratadine and Pseudoephedrine Sulfate, Extended-Release Tablets, USP 10/240mg), 15-count blister packs, Manufactured by: Ohm Laboratories Inc., 1385 Livingston Avenue, North Brunswick, NJ 08902, NDC 63981-724-15

Affected NDC 63981-0724-15

Compare with the code on your package — it is the most precise check available.

Drug: Ephedrine Category: Allergy & Cold Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
KIRKLAND SIGNATURE ALLERCLEAR D 24 HR Extended Release
loratadine and pseudoephedrine sulfate
NDC 63981-0724
LORATADINE 10 mg/1; PSEUDOEPHEDRINE SULFATE 240 mg/1 Tablet, Extended Release
Oral
Kirkland-COSTCO WHOLESALE COMPANY OTC
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
63981-724-15
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0069-2022 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ephedrine recalls

See all
Class II · Moderate risk

Ephedrine Plus

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation NDC 65193-320-24 D-0473-2022

Other recalls by Sun Pharmaceutical Industries INC

All 2021 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026